Cardiol Therapeutics Inc. (CRDL)
NASDAQ: CRDL · Real-Time Price · USD
1.805
+0.005 (0.28%)
Aug 18, 2026, 11:33 AM EDT - Market open
Cardiol Therapeutics Balance Sheet
Financials in millions CAD. Fiscal year is January - December.
Millions CAD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 26.08 | 21.42 | 30.58 | 34.93 | 59.47 | 83.9 |
Cash & Short-Term Investments | 26.08 | 21.42 | 30.58 | 34.93 | 59.47 | 83.9 |
Cash Growth | 43.34% | -29.97% | -12.46% | -41.26% | -29.12% | 498.20% |
Accounts Receivable | - | - | - | - | - | 0.07 |
Other Receivables | 0.31 | 0.23 | 0.36 | 0.28 | 0.48 | 0.34 |
Receivables | 0.31 | 0.23 | 0.36 | 0.28 | 0.48 | 0.41 |
Prepaid Expenses | 2.83 | 1.86 | 0.73 | 0.94 | 1.49 | 2.83 |
Total Current Assets | 29.23 | 23.5 | 31.67 | 36.15 | 61.44 | 87.14 |
Property, Plant & Equipment | 0.13 | 0.12 | 0.2 | 0.34 | 0.3 | 0.36 |
Other Intangible Assets | - | - | - | 0.21 | 0.29 | 0.38 |
Total Assets | 29.36 | 23.62 | 31.86 | 36.7 | 62.03 | 87.88 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 3.75 | 3.48 | 6.98 | 7.62 | 8.35 | 4.14 |
Accrued Expenses | - | - | - | 0.42 | 0.99 | 0.72 |
Current Portion of Leases | 0.04 | 0.04 | 0.03 | 0.02 | 0.05 | 0.04 |
Other Current Liabilities | 1.47 | 2.14 | - | 0.24 | 0.42 | 6.66 |
Total Current Liabilities | 5.26 | 5.66 | 7.01 | 8.3 | 9.8 | 11.57 |
Long-Term Leases | 0.07 | 0.09 | 0.13 | 0.16 | 0.02 | 0.07 |
Total Liabilities | 5.33 | 5.74 | 7.14 | 8.45 | 9.83 | 11.64 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 221.01 | 201.87 | 179.34 | 148.52 | 147.55 | 142.92 |
Additional Paid-In Capital | 30.18 | 29.08 | 24.65 | 18.79 | 15.59 | 12.66 |
Retained Earnings | -229.97 | -213.07 | -179.25 | -142.58 | -114.45 | -83.52 |
Comprehensive Income & Other | 2.82 | - | - | 3.52 | 3.52 | 4.18 |
Shareholders' Equity | 24.03 | 17.88 | 24.73 | 28.25 | 52.2 | 76.24 |
Total Liabilities & Equity | 29.36 | 23.62 | 31.86 | 36.7 | 62.03 | 87.88 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 0.11 | 0.13 | 0.16 | 0.17 | 0.07 | 0.12 |
Net Cash (Debt) | 25.97 | 21.29 | 30.42 | 34.76 | 59.4 | 83.78 |
Net Cash Growth | 43.88% | -30.01% | -12.47% | -41.48% | -29.10% | 504.11% |
Net Cash Per Share | 0.26 | 0.24 | 0.43 | 0.54 | 0.95 | 1.94 |
Filing Date Shares Outstanding | 116.82 | 111.87 | 82.61 | 68.27 | 64.1 | 61.93 |
Total Common Shares Outstanding | 115.88 | 100.26 | 82.61 | 65.35 | 64.04 | 61.92 |
Working Capital | 23.96 | 17.85 | 24.66 | 27.86 | 51.63 | 75.58 |
Book Value Per Share | 0.21 | 0.18 | 0.30 | 0.43 | 0.82 | 1.23 |
Tangible Book Value | 24.03 | 17.88 | 24.73 | 28.04 | 51.91 | 75.86 |
Tangible Book Value Per Share | 0.21 | 0.18 | 0.30 | 0.43 | 0.81 | 1.23 |
Machinery | 0.7 | 0.41 | 0.39 | 0.42 | 0.35 | 0.28 |
Leasehold Improvements | - | 0.24 | 0.24 | 0.24 | 0.24 | 0.24 |